Syndromic Multiplex Polymerase Chain Reaction: The Impact on Microbial Yield in Nonventilator Hospital-Acquired Pneumonia
Open Forum Infectious Diseases · 28.04.2026 · 13 (5)
DOI: 10.1093/ofid/ofag272 ↗Kurz gefasst
Fachartikel in der Zeitschrift Open Forum Infectious Diseases, online erschienen am 05.05.2026. Verfasst von Jon Anders Feet und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Science, Bergen Integrated Diagnostic Stewardship Cluster, Faculty of Medicine, University of Bergen, Norway. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Trond Mohn Foundation, Research Council of Norway, Helse Vest.
Themen: Pneumonieprophylaxe
Abstract (Originalsprache)
Background
Nonventilator hospital-acquired pneumonia (NV-HAP) is a leading cause of hospital-acquired infection, associated with substantial morbidity and mortality. Conventional bacterial cultures from lower respiratory tract specimens, as recommended by current guidelines, have limited sensitivity and frequently fail to identify causative pathogens. This study evaluated a rapid, culture-independent molecular diagnostic approach versus standard methods for identifying microbial etiology, assessing antimicrobial prescribing, and determining NV-HAP incidence in a medium-sized Norwegian hospital. We hypothesized that multiplex polymerase chain reaction (mPCR) would shorten time to diagnosis and increase microbial yield.
Method
A screening process twice daily was established to prospectively identify NV-HAP patients eligible for inclusion in a single hospital from 11 June 2021 to 26 November 2024. Lower respiratory tract samples were analyzed using a syndromic multiplex PCR assay and compared with conventional culture methods.
Results
Eighty-six patients were included, with bacterial pathogens detected in 51.2% of the samples analyzed by mPCR and in 23.5% of cultured samples (P < .01). Median time to microbiological results were 2.5 (2–10) hours for mPCR and 45.8 (26.9–50.3) hours for bacterial culture (P < .01). Overall agreement was fair to moderate (κ = 0.39), with an observed agreement of 69%. Antibiotic therapy was modified based on the mPCR in 13 patients (15.1%) and due to culture in 9 patients (10.5%).
Conclusions
The use of syndromic mPCR provided faster results and a higher detection rate for microbial etiology compared to traditional culture methods.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Clinical Science, Bergen Integrated Diagnostic Stewardship Cluster, Faculty of Medicine, University of Bergen, Norway.
- Department of Medicine, Drammen Hospital, Vestre Viken Hospital Trust, Drammen, Norway.
- Department of Microbiology, Haukeland University Hospital, Bergen, Norway.
ORCID-Profile: Jon Anders Feet, Karl Erik Müller, Øyvind Kommedal, Elling Ulvestad, Harleen M S Grewal, Lars Heggelund
Förderung
- Trond Mohn Foundation
- Research Council of Norway
- Helse Vest
- Vestre Viken Hospital Trust
Zitieren
APA
Feet, J. A., Müller, K. E., Kommedal, Ø., Brun, K., Ulvestad, E., Grewal, H. M. S., & Heggelund, L. (2026). Syndromic Multiplex Polymerase Chain Reaction: The Impact on Microbial Yield in Nonventilator Hospital-Acquired Pneumonia. Open Forum Infectious Diseases, 13(5). https://doi.org/10.1093/ofid/ofag272
Vancouver
Feet JA, Müller KE, Kommedal Ø, Brun K, Ulvestad E, Grewal HMS, et al. Syndromic Multiplex Polymerase Chain Reaction: The Impact on Microbial Yield in Nonventilator Hospital-Acquired Pneumonia. Open Forum Infectious Diseases. 2026;13(5). doi:10.1093/ofid/ofag272
BibTeX
@article{Feet2026,
author = {Feet, Jon Anders and Müller, Karl Erik and Kommedal, Øyvind and Brun, Kathrine and Ulvestad, Elling and Grewal, Harleen M S and Heggelund, Lars},
title = {Syndromic Multiplex Polymerase Chain Reaction: The Impact on Microbial Yield in Nonventilator Hospital-Acquired Pneumonia},
journal = {Open Forum Infectious Diseases},
year = {2026},
volume = {13},
number = {5},
doi = {10.1093/ofid/ofag272}
}
EUVIMED